Business
Dare Bioscience, Inc.: Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research.
Revenue increased 10429.4% to $1.0M, while Net income decreased 230.6% to ($13.4M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $1.0MWatch
- Profitability — Net income ($13.4M)Watch
- Cash generation — Free cash flow ($10.3M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Dare Bioscience, Inc. reports it. History and quarterly detail are in the app.
- License And Collaboration Revenues$12.0M
- License fee revenue and other revenue$1.0M
Leadership changes
From Dare Bioscience, Inc.'s own filings, the day they're filed.
- Gregory W. Matz · directors · departureeff. 2026-04-16
- John Fair · Chief Commercial Officer · departureeff. 2024-06-30
- Management Retirement · Chief Financial Officer · departureeff. 2024-01-26
Latest filings
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-24
- 8-K · Company announcement2026-07-17
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Dare Bioscience, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.